By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion disclosed today a settlement agreement that will provide the company with $1 million.

It also said that its stock has been moved to the Nasdaq Capital Market effective Feb. 15.

In a document filed with the US Securities and Exchange Commission, the Austin, Texas-based molecular diagnostics firm said it has settled with an unnamed third party over Vermillion's losses on short- and long-term investments in previous years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.